A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer

Background Lung cancer is the leading cause of cancer-related death in the United States. Nearly 50% of patients with stages I and II non-small cell lung cancer (NSCLC) will die from recurrent disease despite surgical resection. No reliable clinical or molecular predictors are currently available for identifying those at high risk for developing recurrent disease. As a consequence, it is not possible to select those high-risk patients for more aggressive therapies and assign less aggressive treatments to patients at low risk for recurrence. Methods and Findings In this study, we applied a meta-analysis of datasets from seven different microarray studies on NSCLC for differentially expressed genes related to survival time (under 2 y and over 5 y). A consensus set of 4,905 genes from these studies was selected, and systematic bias adjustment in the datasets was performed by distance-weighted discrimination (DWD). We identified a gene expression signature consisting of 64 genes that is highly predictive of which stage I lung cancer patients may benefit from more aggressive therapy. Kaplan-Meier analysis of the overall survival of stage I NSCLC patients with the 64-gene expression signature demonstrated that the high- and low-risk groups are significantly different in their overall survival. Of the 64 genes, 11 are related to cancer metastasis (APC, CDH8, IL8RB, LY6D, PCDHGA12, DSP, NID, ENPP2, CCR2, CASP8, and CASP10) and eight are involved in apoptosis (CASP8, CASP10, PIK3R1, BCL2, SON, INHA, PSEN1, and BIK). Conclusions Our results indicate that gene expression signatures from several datasets can be reconciled. The resulting signature is useful in predicting survival of stage I NSCLC and might be useful in informing treatment decisions.

[1]  R. Weinshilboum,et al.  Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[3]  Mark A. Stephenson,et al.  Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.

[4]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[5]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[6]  A. Hölscher,et al.  MUC1 and Nuclear β-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis , 2004, Clinical Cancer Research.

[7]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[8]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Verdebout,et al.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis , 2003, British Journal of Cancer.

[10]  A. Okamura,et al.  Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. , 2002, Lung cancer.

[11]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[12]  C. Dang,et al.  Histopathological and Molecular Prognostic Markers in Medulloblastoma: c‐myc, N‐myc, TrkC, and Anaplasia , 2004, Journal of neuropathology and experimental neurology.

[13]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Botstein,et al.  Variation in gene expression patterns in human gastric cancers. , 2003, Molecular biology of the cell.

[15]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[16]  T. Kuo,et al.  Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma , 2005, Modern Pathology.

[17]  Dimitrios H Roukos,et al.  Perspectives in the treatment of gastric cancer , 2005, Nature Clinical Practice Oncology.

[18]  Guoying Liu,et al.  NetAffx: Affymetrix probesets and annotations , 2003, Nucleic Acids Res..

[19]  David Sidransky,et al.  Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival , 2001, Oncogene.

[20]  J. Luketich,et al.  New therapeutic approaches for early stage non-small cell lung cancer. , 2005, Surgical oncology.

[21]  M. Volm,et al.  Characteristics of long-term survivors of untreated lung cancer. , 2002, Lung cancer.

[22]  Zhiyuan Hu,et al.  Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay , 2006, Breast Cancer Research.

[23]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[24]  K. Yarasheski,et al.  Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. , 2005, Metabolism: clinical and experimental.

[25]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[26]  Jing Yang,et al.  Identification of Differentially Expressed Genes Contributing to Radioresistance in Lung Cancer Cells using Microarray Analysis , 2005, Radiation research.

[27]  Charles A Powell,et al.  Molecular signatures in biopsy specimens of lung cancer. , 2004, American journal of respiratory and critical care medicine.

[28]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. , 2004, Cancer cell.

[29]  B. Savaş,et al.  Distribution of Bcl-2 gene expression and its prognostic value in non-small cell lung cancer. , 2005, Tuberkuloz ve toraks.

[30]  Douglas C McCrory,et al.  Screening for lung cancer: a review of the current literature. , 2003, Chest.

[31]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[32]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Mountain,et al.  Regional lymph node classification for lung cancer staging. , 1997, Chest.

[34]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[35]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[36]  H. Drexler,et al.  FLT3: receptor and ligand. , 2004, Growth factors.

[37]  Joanna H Shih,et al.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Baltagi,et al.  Econometric Analysis of Panel Data , 2020, Springer Texts in Business and Economics.

[39]  G. Ehninger,et al.  MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia , 2005, British journal of haematology.

[40]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[41]  Yu Shyr,et al.  A training-testing approach to the molecular classification of resected non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  J. Bernaudin,et al.  Multidrug resistance‐associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non‐small cell lung cancer (NSCLC) , 2005, International journal of cancer.

[43]  M. Ohira,et al.  Aberrant methylation of FBN2 in human non-small cell lung cancer. , 2005, Lung cancer.

[44]  G. Silvestri,et al.  One hundred years of lung cancer. , 2005, American journal of respiratory and critical care medicine.

[45]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[46]  Jiang Gui,et al.  Partial Cox regression analysis for high-dimensional microarray gene expression data , 2004, ISMB/ECCB.

[47]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[48]  H. Drexler,et al.  Mini ReviewFLT3: Receptor and Ligand , 2004 .

[49]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[50]  Daniel Q. Naiman,et al.  Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data , 2005, Bioinform..

[51]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[52]  J. Minna,et al.  Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification , 2002, Oncogene.

[53]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.